be associated with poor quality of life. However, cirrhotic patients have limited access to many therapeutic drugs metabolized primarily in liver due to decreased liver function. Indeed, to date, a well- established therapy for cramp in liver cirrhosis is still lacking. This is the first randomized placebo-controlled trial of pregabalin in the treatment of muscle cramps in patients with liver cirrhosis. Here, we aimed to assess efficacy and safety of pregabalin against frequent muscle cramp with liver cirrhosis. And we also investigate the relationship of muscle cramps with quality of life (QOL) using 36-item Short-Form Health Survey (SF-36) and Liver Disease Quality of Life instrument (LDQOL). Method: In our randomized, double-blind, placebo-controlled study, we enrolled participants up to 75 years old with diagnosed liver cirrhosis at the Seoul Metropolitan Government Boramae Medical Center from July 2011 to Dec 2017. The patients randomlyallocated into the treatment (pregabalin) and placebo (dummy) groups, by a web-based randomization program. The primary outcome was the reduction rate of the frequency of muscle cramps in both groups. We assessed the primary outcome in all participants who received at least one dose and had at least one LDQOL and SF 36 measurement. We monitored adverse events in all participants. This study is registered with ClinicalTrials.gov, number NCT01271660 Results: Between July 2011, and February 2018, we enrolled 63 participants (30 randomly allocated pregabalin, 30 randomly allo- cated placebo, and 3 withdrew). In the pregabalin group, the reduction rate of the frequency of muscle cramps was significantly higher than placebo group (p < 0.005). The reduction rate of pain and frequency of muscle cramp during sleep did not differ in both groups. Two domains of SF-36, “Role limitations due to physical health” and “Pain”, and one domain of LDQOL scores, “Symptoms”, showed significant differences between the placebo and the pregabalin group ( p < 0.05). Conclusion: Pregabalin is generally well tolerated in cirrhotic patients and reduces the frequency of muscle cramp over placebo. Our trial showed pregabalin will be good candidate for cramp treatment in cirrhotic patients. PS-085 The impact of ABO blood group on von Willebrand factor levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease Bernhard Scheiner 1 , Prof. Patrick G. Northup, M.D. 2 , Anselm B. Gruber 1 , Gerda Leitner 3 , Prof. Peter Quehenberger, MD 4 , Michael Trauner 1 , Thomas Reiberger 1 , Ton Lisman 5 , Mattias Mandorfer 1 . 1 Medical University of Vienna, Department of Gastroenterology and Hepatology, Vienna, Austria; 2 University of Virginia, Division of Gastroenterology and Hepatology, Charlottesville, United States; 3 Medical University of Vienna, Department of Blood Group Serology and Transfusion Medicine, Vienna, Austria; 4 Medical University of Vienna, Department of Laboratory Medicine, Vienna, Austria; 5 University of Groningen, Surgical Research Laboratory and Section of Hepatobiliary Surgeryand Liver Transplantation, Department of Surgery, Groningen, Netherlands Email: mattias.mandorfer@meduniwien.ac.at Background and aims: Non-O ABO blood group (BG) is a risk factor for arterial and venous thromboses in the general population, which has been attributed to the effect of BG on von Willebrand factor (VWF) plasma levels. Patients with cirrhosis commonly develop venous thrombosis, especially portal vein thrombosis (PVT). Procoagulant alterations, such as high VWF plasma levels, have been suggested as a risk factor. We aimed to assess (1) if BG is a risk factor for PVT and (2) whether BG impacts VWF plasma levels in patients with advanced chronic liver disease (ACLD). Method: Retrospective analysis including two patient cohorts: (1) ‘US’ cohort including all adult liver transplantations in the US between 2002-2017 and (2) ‘Vienna’ cohort comprising patients undergoing hepatic venous pressure gradient (HVPG)-measurement at the Medical University of Vienna between 2006-2018 who had an HVPG ≥ 6mmHg and available information on BG and VWF plasma levels. Results: (1) The ‘US’ cohort comprised 84947 patients. 55% had a non-O BG and except for ethnicity, we observed no relevant differences in patient characteristics between patients with BG O and non-O. Importantly, the prevalence of PVT at the time of liver transplantation was similar between groups (O: 9.6% vs. non-O: 9.3%; panel A). (2) 420 patients were included in the ‘Vienna’ cohort; 64% with a non-O BG. Mean HVPG was 18 ± 6mmHg and 90% of patients had clinically significant portal hypertension (HVPG ≥ 10mmHg). VWF plasma levels were markedly increased, in a manner proportional to the degree of hepatic impairment (Child-Turcotte-Pugh: +16.5% VWF per point in adjusted analysis; panel B) and severity of portal hypertension (HVPG: +4.1% VWF per mmHg in adjusted analysis; panel C). VWF plasma levels were slightly higher in patients with a non-O BG (319 (162)% vs. 312 (175)%, p = 0.047 in unadjusted analysis; +23.6% VWF in adjusted analysis; panel D). Conclusion: Elevated VWF plasma levels are related to the severity of liver disease with only a minor contribution of BG. BG was not a risk factor for PVT in a very large dataset, and this lack of association could be explained by the minor effect of BG on VWF plasma levels. Alternatively, hypercoagulability, forexample caused byelevatedVWF levels mayonly have a minor impact on PVTrisk in patients with ACLD. PS-086 Sustained virologic response in patients with cirrhosis from chronic hepatitis C leads to sustained and long-term improvement of health-related quality of life, fatigue, and work productivity Zobair Younossi 1,2 , Maria Stepanova 3 , Andrei Racilla 3 , Ira Jacobson 4 , Andrew Muir 5 , Stefan Zeuzem 6 , Eric Lawitz 7 , Stanislas Pol 8 , Anuj Gaggar 9 , Robert Myers 9 , Issah Younossi 3 , Fatema Nader 3 . 1 Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, United States; 2 Center for Liver Diseases-Department of Medicine, Inova Fairfax Medical Campus, Falls Church, United States; 3 Center for Outcomes Research in Liver Disease, Washington DC, United States; 4 NYU Langone Health, New York, United States; 5 Duke Clinical Research, Durham, United States; 6 Universitatsklinikum, Frankfurt, Germany; 7 Texas Liver Institute, San Antonio, United States; 8 Hopital Cochin, Paris, France; 9 Gilead Science, Foster City, United States Email: zobair.younossi@inova.org Background and aims: Patients with chronic hepatitis C (CHC) and cirrhosis have severe impairment of health-related quality of life ORAL PRESENTATIONS e54 Journal of Hepatology 2019 vol. 70 | e45–e80